<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964312</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-CP-302</org_study_id>
    <nct_id>NCT02964312</nct_id>
  </id_info>
  <brief_title>LATERA-OFFICE Study</brief_title>
  <official_title>Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OFFICE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirox, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Arch Consulting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spirox, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, nonrandomized, single-arm controlled study to obtain outcomes data
      in participants with severe to extreme class NOSE scores who are undergoing placement of the
      Spirox Latera Implant with or without concurrent turbinate reduction procedures in an office
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm intervention with pre/post comparison for treatment response.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percent of Treatment Responders</measure>
    <time_frame>6 months</time_frame>
    <description>A responder is defined as a participant who has an improvement of at least 1 NOSE class or a NOSE score reduction of at least 20% compared with baseline. NOSE scores can range from 0 to 100 with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75) and extreme (80-100).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Procedure- and/or Device-related Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with 1 or more adverse events that are determined to be related to the Latera implant and/or procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Treatment Responders</measure>
    <time_frame>1, 3, 12, 18, and 24 months post procedure.</time_frame>
    <description>A responder is defined as a participant who has an improvement of at least 1 NOSE class or a NOSE score reduction of at least 20% compared with baseline. NOSE scores can range from0 to 100 with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75) and extreme (80-100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasal Airway Obstruction From Baseline Using a Visual Analog Scale (VAS)</measure>
    <time_frame>1,3, 6, 12, 18, and 24 months post procedure</time_frame>
    <description>Change from baseline in the nasal obstryction VAS score. Participants provide scores on a scale of 0 (easy to breathe through the nose) to 100 (difficult to breathe through the nose) using a 100-mm line with 1-mm increments).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and Device-related Adverse Events</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Number of participants who experience procedure- or device-related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Nasal Obstruction</condition>
  <arm_group>
    <arm_group_label>Latera Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal Implant</intervention_name>
    <description>Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.</description>
    <arm_group_label>Latera Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has Nasal Obstruction Symptom Evaluation (NOSE) score ≥55.

          2. The subject has dynamic lateral nasal wall insufficiency as confirmed by positive
             modified Cottle maneuver.

          3. The subject is ≥18 years of age.

          4. The subject is willing and able to provide informed consent and comply with the study
             protocol.

          5. The subject is seeking treatment for nasal airway obstruction due to nasal valve
             collapse (NVC) and is willing to undergo an in-office nasal implant procedure alone or
             with a turbinate reduction procedure.

          6. The subject has appropriate nasal and facial anatomy to receive the Latera Implant.

          7. The subject agrees to follow-up examinations through 12 months post operatively.

          8. The subject has failed to benefit from appropriate maximal medical management [eg,
             nasal steroids (at least 4 weeks); antihistamines; oral decongestants; nasal strips,
             stents, or cones]. Failure of maximal medical management may be from lack of
             effectiveness or tolerability.

        Exclusion Criteria:

          1. The subject is having a concurrent functional endoscopic sinus surgery (FESS) or
             sinuplasty.

          2. The subject has had rhinoplasty within the past 12 months.

          3. The subject is planning to have other concurrent rhinoplasty procedure.

          4. The subject is planning to have other rhinoplasty procedures or will use external
             dilators within 12 months after the index procedure.

          5. The subject has had septoplasty and/or inferior turbinate reduction within the past 6
             months.

          6. The subject has, in the view of the clinician, inappropriate fixation on their nasal
             airway.

          7. The subject plans to have any surgical or nonsurgical treatment of their nasal valve,
             other than the index procedure, within 12 months of the study.

          8. The subject has a permanent Implant or dilator in the nasal area.

          9. The subject has concomitant inflammatory or infectious skin conditions or unhealed
             wounds in the treatment area.

         10. The subject currently has active nasal vestibulitis.

         11. The subject has a history of nasal vasculitis.

         12. The subject is a chronic systemic steroid or recreational intranasal drug user.

         13. The subject has had a cancerous or precancerous lesion and/or has had radiation
             exposure in the treatment area or chemotherapy.

         14. The subject has polyps or pathology (ie, septal deviation) other than turbinate
             hypertrophy and/or lateral wall insufficiency that would contribute to airway
             obstruction.

         15. The subject has a history of a significant bleeding disorder(s) that would prevent
             healing of the treatment area post procedure.

         16. The subject has a known or suspected allergy to polylactide polymer (PLA) or other
             absorbable materials.

         17. The subject has a significant systemic disease such as poorly controlled diabetes
             which, in the investigator's opinion, could predispose the subject to poor wound
             healing.

         18. The subject is currently using nasal oxygen or continuous positive airway pressure
             (CPAP).

         19. The subject is not a candidate for procedures conducted under local anesthesia and/or
             managed anesthesia care (MAC) or conscious sedation.

         20. Female subjects of childbearing potential, known or suspected to be pregnant, or is
             lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Sidle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beverly Hills Aesthetic Surgical Institute</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alessi Institute For Facial Plastic Surgery</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT Assoc. of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sinus, Allergy, &amp; Sleep Wellness</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Nasal &amp; Sinus Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison ENT &amp; Facial Plastic Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collin County ENT</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogden Clinic</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sidle DM, Stolovitzky P, Ow RA, Silvers S, Matheny K, Bikhazi N, Wani M, Scurry WC, Most SP. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. Laryngoscope. 2020 May;130(5):1132-1137. doi: 10.1002/lary.28151. Epub 2019 Jun 28.</citation>
    <PMID>31254279</PMID>
  </results_reference>
  <results_reference>
    <citation>Stolovitzky P, Senior B, Ow RA, Mehendale N, Bikhazi N, Sidle DM. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. Int Forum Allergy Rhinol. 2019 Aug;9(8):850-856. doi: 10.1002/alr.22362. Epub 2019 Jun 21.</citation>
    <PMID>31226238</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <results_first_submitted>October 9, 2019</results_first_submitted>
  <results_first_submitted_qc>October 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal valve collapse</keyword>
  <keyword>absorbable nasal implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02964312/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Latera Implant</title>
          <description>Nasal Implant
Nasal Implant: Latera implant will be placed in stand alone procedure or in conjunction with a turbinate reduction procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled and treated with the Latera Implant.</population>
      <group_list>
        <group group_id="B1">
          <title>Latera Implant</title>
          <description>Nasal Implant
Nasal Implant: Latera implant will be placed in stand alone procedure or in conjunction with a turbinate reduction procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Specified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NOSE score (100-point scale)</title>
          <description>Nasal symptoms were evaluated using the Nasal Obstruction Symptom Evaluation (NOSE) score, a patient-reported questionnaire. The NOSE score involves rating the severity of 5 nasal symptoms (congestion, obstruction, trouble breathing, sleeping, and exercise) on a scale of 0 to 4. The values are totaled and multiplied by 5 to provide a scale of 0-100 with higher scores indicating worse symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nose Severity Class</title>
          <description>NOSE severity classes are defined as Mild (5-25), Moderate (30-50), Severe (55-75), and Extreme (80-100).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Obstruction Visual Analog Scale (VAS)</title>
          <description>Patient-reported instrument used to capture the participants' perception of their ability to breathe through the nose. The VAS consists of a 100-mm horizontal line marked in 1-mm increments with 0-mm indicating &quot;no difficulty breathing through the nose&quot; and 100-mm indicating &quot;unable to breathe through the nose&quot;. The participant marks the point on the line that indicates their current perception.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percent of Treatment Responders</title>
        <description>A responder is defined as a participant who has an improvement of at least 1 NOSE class or a NOSE score reduction of at least 20% compared with baseline. NOSE scores can range from 0 to 100 with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75) and extreme (80-100).</description>
        <time_frame>6 months</time_frame>
        <population>All participants who had placement of 1 or more Latera implants and had a 6-month NOSE score.</population>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent of Treatment Responders</title>
          <description>A responder is defined as a participant who has an improvement of at least 1 NOSE class or a NOSE score reduction of at least 20% compared with baseline. NOSE scores can range from 0 to 100 with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75) and extreme (80-100).</description>
          <population>All participants who had placement of 1 or more Latera implants and had a 6-month NOSE score.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the proportion of responders at 6 months would be 50%. Since there was not direct comparison group, the hypothesis was set as a superiority comparison to a target proportion (66%) with a power level &gt;90%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Proportion</param_type>
            <param_value>89.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.5</ci_lower_limit>
            <ci_upper_limit>93.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Procedure- and/or Device-related Adverse Events</title>
        <description>Number of participants with 1 or more adverse events that are determined to be related to the Latera implant and/or procedure.</description>
        <time_frame>6 months</time_frame>
        <population>All participants who received 1 or more Latera implants.</population>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Procedure- and/or Device-related Adverse Events</title>
          <description>Number of participants with 1 or more adverse events that are determined to be related to the Latera implant and/or procedure.</description>
          <population>All participants who received 1 or more Latera implants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Treatment Responders</title>
        <description>A responder is defined as a participant who has an improvement of at least 1 NOSE class or a NOSE score reduction of at least 20% compared with baseline. NOSE scores can range from0 to 100 with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75) and extreme (80-100).</description>
        <time_frame>1, 3, 12, 18, and 24 months post procedure.</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nasal Airway Obstruction From Baseline Using a Visual Analog Scale (VAS)</title>
        <description>Change from baseline in the nasal obstryction VAS score. Participants provide scores on a scale of 0 (easy to breathe through the nose) to 100 (difficult to breathe through the nose) using a 100-mm line with 1-mm increments).</description>
        <time_frame>1,3, 6, 12, 18, and 24 months post procedure</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction Questionnaire</title>
        <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
        <time_frame>6 months</time_frame>
        <population>All participants who completed a satisfaction questionnaire at the 6-month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Latera Implant</title>
            <description>Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
Nasal Implant: Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction Questionnaire</title>
          <description>Participants rate whether they are satisfied or not satisfied with the procedure and cosmetic appearance after the procedure. The percent of participants reporting satisfaction with the procedure is reported.</description>
          <population>All participants who completed a satisfaction questionnaire at the 6-month visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure and Device-related Adverse Events</title>
        <description>Number of participants who experience procedure- or device-related adverse events.</description>
        <time_frame>12 months post procedure</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Latera Implant</title>
          <description>Nasal Implant
Nasal Implant: Latera implant will be placed in stand alone procedure or in conjunction with a turbinate reduction procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implant migration/retrieval</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Clinical Research &amp; Publications Manager</name_or_title>
      <organization>Stryker ENT</organization>
      <phone>763-463-1598</phone>
      <email>ellen.omalley@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

